Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

T cells are critical effectors of cancer immunotherapies, but little is known about their gene
expression programs in diffuse gliomas. Here, we leverage single-cell RNA sequencing …

Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …

Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt
from central tolerance, can generate robust immune responses, and can function as bona …

Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or
progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH) …

Chimeric antigen receptor (CAR)-T-cell therapy for solid tumors is limited due to
heterogeneous target antigen expression and outgrowth of tumors lacking the antigen …

Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …

Glioblastoma is the most common primary central nervous system malignancy and has a
poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant …

Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …